Announced Sat, 26 Sept, 2026 · 15:07 IST

Trading window closed from October 1, 2026 till 48 hours after Q2 results

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.7%Reaction day

₹232.00

prior close

₹238.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.6%+2.3% vs market

Pharmaceuticals peers, median of 172sector-1.5%+2.2% vs sector

On the reaction day the stock moved 2.3 pts more than Nifty Microcap 250 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.3

15m

-0.3

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.7-1.6+2.3-1.5+2.2

Next day

+3.4-0.6+4.0-1.0+4.4

+0.3-0.8+1.1-1.9+2.2

+0.0-2.1+2.1-2.5+2.5

+3.7-2.1+5.8-3.4+7.1

+3.0-0.8+3.8-2.4+5.4

+1.7-3.8+5.5-4.3+5.9

15d

+18.0-6.9+24.9-7.9+25.9

+14.7pendingpending-6.6+21.2

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Samrat Pharmachem has informed BSE that the trading window for its shares will remain closed from Thursday, October 1, 2026, until 48 hours after the company declares its Un-Audited Financial Results for the quarter ended September 30, 2026. The closure is in line with SEBI Insider Trading Regulations, 2015. All Designated Persons and their immediate relatives are barred from buying, selling, or pledging shares during this window. This is a routine compliance measure taken ahead of the upcoming quarterly earnings announcement.

Likely market impact

Routine regulatory filing. Insiders cannot trade until Q2 FY27 results are out. No direct impact on retail shareholders.